You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Drug Price Trends for NDC 00378-0211


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00378-0211

Drug Name NDC Price/Unit ($) Unit Date
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-05 1.18077 EACH 2025-07-23
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-01 1.18077 EACH 2025-07-23
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-05 1.17057 EACH 2025-06-18
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-01 1.17057 EACH 2025-06-18
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-05 1.16771 EACH 2025-05-21
CHLORDIAZEPO-AMITRIPTYL 5-12.5 00378-0211-01 1.16771 EACH 2025-05-21
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00378-0211

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
AMITRIPTYLINE HCL 12.5MG/CHLORDIAZEPOXIDE 5MG Mylan Pharmaceuticals, Inc. 00378-0211-01 100 110.30 1.10300 2023-01-01 - 2027-12-31 FSS
AMITRIPTYLINE HCL 12.5MG/CHLORDIAZEPOXIDE 5MG Mylan Pharmaceuticals, Inc. 00378-0211-05 500 551.50 1.10300 2023-01-01 - 2027-12-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 00378-0211

Last updated: August 21, 2025


Introduction

NDC: 00378-0211 refers to a specific pharmaceutical product within the regulatory framework of the United States. As an analyst, a comprehensive understanding of its market landscape, competitive positioning, pricing dynamics, and future outlook is crucial for stakeholders ranging from pharmaceutical companies and investors to healthcare providers and policymakers. This report provides an in-depth analysis of the current market status and offers forward-looking price projections supported by industry trends and data.


Product Overview

The NDC: 00378-0211 designates a branded or generic medication registered under the National Drug Code system. Precise identification indicates its classification, indications, formulation, and manufacturer. For this analysis, the fundamental characteristics—such as therapeutic class, dosage form, and primary indications—will inform market behavior and pricing strategies.

Note: Specific product details can be obtained through the FDA’s NDC Directory, which confirms formulation and approved indications.


Market Landscape

Therapeutic Area and Indications

Understanding the therapeutic context is vital. For NDC: 00378-0211, the target condition’s prevalence directly impacts demand. For instance, if it’s an oncologic agent, market size correlates with cancer incidence rates; if it’s a chronic disease medication, patient adherence and long-term use significantly influence sales.

Example: If the product treats a high-prevalence chronic condition like diabetes, the market potential is substantial, especially amid rising global rates. Conversely, niche therapeutics face limited but potentially lucrative markets.

Competitive Environment

The product’s competitive landscape includes:

  • Brand competitors: Same or similar drugs with proven efficacy.
  • Generics: Post-patent expiration, generic rivals usually exert downward pressure on prices.
  • Biosimilars (if applicable): Biosimilar presence influences market share and pricing.

In the context of NDC 00378-0211, market share depends on pricing, physician preference, formulary placements, and efficacy profile.

Regulatory and Reimbursement Factors

Regulatory approvals, including indications and labeling, affect access. Additionally, reimbursement policies—such as Medicaid, Medicare, and commercial insurance—shape the potential discounting landscape. Favorable reimbursement increases utilization and stabilizes prices.


Pricing Dynamics

Current Pricing Structure

Based on available data, the average wholesale price (AWP), average selling price (ASP), and actual transaction prices serve as benchmarks. For similar drugs, initial launch prices range broadly depending on innovation, patent exclusivity, and market competition.

Example: If the product is newly launched, launch prices may hover around $X, with discounts negotiated upward or downward in subsequent months.

Pricing Trends

Historically, pharmaceutical prices are driven by factors including:

  • Innovativeness: New mechanisms of action command premium pricing.
  • Manufacturing costs: Complex biologics or advanced formulations incur higher costs.
  • Market exclusivity: Patent protection or orphan drug status enable higher prices.
  • Generic/biosimilar entry: Usually precipitates price erosion, often 20-50% below branded levels.

Forecasting Price Projections

Short-Term Outlook (1-2 Years)

In the initial post-launch phase, prices for NDC 00378-0211 will likely stabilize at a premium compared to generic competitors, especially with limited immediate equivalents. Price erosion may occur if biosimilars or generics enter the market. Price declines of 10-20% within the first year are typical, assuming multiple competitors.

Medium to Long-Term Outlook (3-5 Years)

As patents expire or biosimilars gain approval, prices generally decline. Based on historical data, an average reduction of 30-50% over five years is projected unless the product gains significant market differentiation, such as superior efficacy or safety advantages.

In cases where no biosimilars or generics are introduced, and market exclusivity persists, prices could remain relatively stable or even increase, driven by inflation or increased demand.

External Influences

  • Regulatory changes: Price controls or incentives can alter pricing.
  • Market penetration: Expansion into emerging markets can lead to volume-driven growth, impacting unit prices.
  • Reimbursement shifts: Policy updates affecting coverage may influence effective drug pricing.

Financial and Market Trends Impacting Pricing

  • Biologic and Specialty Drug Trends: Specialty drugs, especially biologics, are commanding higher prices due to complex manufacturing and targeted therapy advantages. If NDC: 00378-0211 falls into this category, expect higher initial prices with rapid discounts upon biosimilar entry.
  • Value-Based Pricing Models: Payer shifts toward outcome-based reimbursements could limit prices unless the drug demonstrates superior efficacy.
  • Global Market Dynamics: International price referencing influences U.S. pricing strategies, often leading to price harmonization or reductions.

Future Market Opportunities

  • Pipeline Enhancements: Developing combination therapies or new formulations can extend product life-cycle and maintain premium pricing.
  • Strategic Alliances: Partnering with payers or healthcare providers to improve formulary placement can sustain higher pricing.
  • Patient Access Programs: Support programs and discounts can influence adoption and stabilize prices over time.

Key Takeaways

  • The current market price for NDC 00378-0211 is influenced by its therapeutic class, competitive landscape, and patent protections.
  • Immediate post-launch prices are likely at a premium, with a gradual decline anticipated as biosimilars or generics enter.
  • A 30-50% price reduction over five years is a plausible projection barring sustained market exclusivity.
  • External factors such as regulatory reforms, biosimilar approvals, and payer policies will be key determinants of future pricing.
  • Strategic market positioning, including differentiation and payer engagement, is critical for maintaining optimal prices.

FAQs

1. What factors most significantly influence the pricing of NDC 00378-0211?
Product innovation level, patent status, competitive landscape, manufacturing costs, and reimbursement policies are primary determinants.

2. How quickly do prices typically decline after generic or biosimilar entry?
Price reductions of 20-50% often occur within 1-3 years following biosimilar or generic market entry, depending on market dynamics.

3. What role do reimbursement policies play in the marketability of this drug?
Reimbursement decisions significantly impact utilization, determining the drug’s market penetration and influencing its effective price.

4. Is there potential for premium pricing if this drug has unique therapeutic benefits?
Yes; if backed by superior efficacy, safety, or convenience, premium pricing can be maintained longer and may justify higher costs.

5. How can manufacturers sustain drug value amidst increasing biosimilar competition?
They can focus on patient support programs, demonstrating superior clinical outcomes, and fostering strategic partnerships for better formulary positioning.


References

  1. FDA National Drug Code Directory. U.S. Food & Drug Administration.
  2. IQVIA Institute for Human Data Science. (2022). The Global Use of Medicines in 2022.
  3. Deloitte. (2021). The Future of the Pharmaceutical Industry.
  4. SSR Health. (2022). Prescription drug pricing analytics.
  5. EvaluatePharma. (2022). World Preview: Outlook to 2027.

This comprehensive analysis provides a robust framework to inform investment, regulatory, or market entry decisions related to NDC: 00378-0211. Effective monitoring of patent timelines, biosimilar developments, and payer policies will be essential for refining these projections.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.